Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Steveminon Dec 28, 2020 12:13pm
138 Views
Post# 32187580

RE:RE:RE:Merry Christmas

RE:RE:RE:Merry ChristmasBullknit, how do you know Integrasyn is much more cost effective than yeast or other processes? I have followed Inmed for years and I have seen zero cost structures for Integrasyn. I wouldn't be so fast to make that statement unless you do in fact have some insider info you'd like to share.
Inmed (Adams) has been very evasive not only aout cost structure but also speaking about the biological burden they ran into and have never offered and explanation.
They were working with Almac in regards to finding the new fusion of enzymes to facilitate the process. They have moved on to Baymedica to allow them access just to "assess the potential of one or more of InMed's high-efficiency enzyme gene sequences in BayMedica's systems". 

So, as you can glean from this, Inmed is not anywhere near commercial scale up - they are still trying to assess the validity of the new enzymatic pathway. Something that apparently Almac couldn't accomplish.

<< Previous
Bullboard Posts
Next >>